JPMorgan Chase & Co. Invests $314,000 in BiomX Inc. (NYSEMKT:PHGE)

JPMorgan Chase & Co. acquired a new position in BiomX Inc. (NYSEMKT:PHGE) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 429,990 shares of the company’s stock, valued at approximately $314,000. JPMorgan Chase & Co. owned approximately 2.37% of BiomX as of its most recent SEC filing.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of BiomX in a research note on Friday, April 4th.

BiomX Trading Down 22.2 %

Shares of PHGE opened at $0.58 on Friday. The stock’s fifty day simple moving average is $0.59 and its 200 day simple moving average is $0.69. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $14.37 million, a P/E ratio of -0.77 and a beta of 1.51. BiomX Inc. has a twelve month low of $0.48 and a twelve month high of $4.90.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.